Hepatitis C virus (HCV) cure rates among those who have received a liver transplant are very good. Publishing their findings in Current Opinion in Gastroenterology, researchers conducted a review of available research on HCV treatment among liver transplantees.

The paper finds that treatment with Sovaldi (sofosbuvir) and ribavirin, Harvoni (ledipasvir/sofosbuvir) and ribavirin, Daklinza (daclatasvir) plus Sovaldi and ribavirin, Sovaldi and Olysio (simeprevir) with or without ribavirin, and Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) have all shown high cure rates among those who have received liver transplants. In fact, cure rates are comparable to those seen among individuals who have not received transplants.

The paper concludes: “In the era of all oral therapies, no patient who undergoes transplant for hepatitis C–related cirrhosis should have their graft fail because of recurrent hepatitis C.”

To read the study, click here (free registration with Medscape is required).